Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Manufacturing
  • Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
  • Manufacturing

Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities

Pharmaceutical Technology

Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.

Read full story

pharminent May 12, 2026 (Last updated: May 16, 2026)

Pharmaceutical Technology

Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
Next: FDA weighs drug repurposing pathway for underserved diseases

Related Stories

  • Manufacturing

Cellares and TScan to assess automated manufacturing of TSC-101 therapy

pharminent June 4, 2026
  • Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb

pharminent June 2, 2026
  • Manufacturing

FUJIFILM opens new iPSC facility in Madison, US

pharminent May 21, 2026

You May Have Missed

  • M&A / Deals

Alzecure enters collaboration and with Lilly for Alzheimer’s project

pharminent June 9, 2026
  • Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026
  • M&A / Deals

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

pharminent June 9, 2026
  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.